- Home
- JBT vs RYTM Comparison
JBT vs RYTM Comparison
Compare JBT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBT
- RYTM
- Stock Information
- Founded
- JBT 1994
- RYTM 2008
- Country
- JBT United States
- RYTM United States
- Employees
- JBT N/A
- RYTM N/A
- Industry
- JBT Industrial Machinery/Components
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- JBT Industrials
- RYTM Health Care
- Exchange
- JBT Nasdaq
- RYTM Nasdaq
- Market Cap
- JBT 3.8B
- RYTM 3.1B
- IPO Year
- JBT N/A
- RYTM 2017
- Fundamental
- Price
- JBT $130.00
- RYTM $56.14
- Analyst Decision
- JBT Buy
- RYTM Strong Buy
- Analyst Count
- JBT 3
- RYTM 10
- Target Price
- JBT $133.67
- RYTM $66.90
- AVG Volume (30 Days)
- JBT 485.8K
- RYTM 530.6K
- Earning Date
- JBT 02-18-2025
- RYTM 02-20-2025
- Dividend Yield
- JBT 0.31%
- RYTM N/A
- EPS Growth
- JBT N/A
- RYTM N/A
- EPS
- JBT 5.38
- RYTM N/A
- Revenue
- JBT $1,693,000,000.00
- RYTM $112,530,000.00
- Revenue This Year
- JBT $5.38
- RYTM $63.80
- Revenue Next Year
- JBT $4.39
- RYTM $44.59
- P/E Ratio
- JBT $24.14
- RYTM N/A
- Revenue Growth
- JBT 1.93
- RYTM 81.55
- 52 Week Low
- JBT $82.64
- RYTM $35.17
- 52 Week High
- JBT $132.61
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- JBT 69.39
- RYTM 47.25
- Support Level
- JBT $121.09
- RYTM $54.29
- Resistance Level
- JBT $132.61
- RYTM $57.00
- Average True Range (ATR)
- JBT 3.73
- RYTM 2.20
- MACD
- JBT 0.42
- RYTM -0.17
- Stochastic Oscillator
- JBT 93.17
- RYTM 46.53
About JBT John Bean Technologies Corporation
John Bean Technologies Corp is a food tech business that provides both customized and turnkey industrial solutions for the food and beverage industry, including a large variety of protein processing and packaging solutions, as well as fruit and juice extraction and ready-to-eat solutions.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.